Skip to main content
. 2019 May 23;14(5):e0216712. doi: 10.1371/journal.pone.0216712

Table 1. Enfuvirtide (T20 Wilcoxon test results).

n = 12 Volunteers; all men; mean age 29.2 ± 1.27. Significance was calculated among absolute values. "p value of change" represents the significance between endpoints after Phase 1 and Phase 2. "p value PREs" represents significance between values in basal circumstances. No changes were significant.

Parameters CHOL HDL LDL TAG GLU mtDNA Crt AST ALT BIL PROTp
Mean
PRE Placebo
181.83 ± 10.9 50.45 ± 2.8 110.64 ± 7.6 85.08 ± 14.6 81.00 ± 2.4 0.713 ± 0.08 1.15 ± 0.03 26.08 ± 2.8 23.33 ± 1.5 0.90 ± 0.10 74.50 ± 2.0
Mean
POST Placebo
173.17 ± 11.6 48.08 ± 2.6 108.00 ± 8.9 85.25 ± 13.1 82.83 ± 2.4 0.625 ± 0.07 1.14 ± 0.03 23.50 ± 1.8 21.17 ± 1.3 0.97 ± 0.16 74.25 ± 1.8
Mean
PRE T20
183.92 ± 13.5 48.25 ± 2.2 118.33 ± 11.4 86.67 ± 10.8 82.50 ± 2.0 0.620 ± 0.05 1.11 ± 0.03 23.45 ± 1.9 22.27 ± 2.4 0.79 ± 0.05 74.27 ± 1.9
Mean
POST T20
172.42 ± 10.1 49.42 ± 2.6 104.42 ± 8.1 92.75 ± 13.8 84.75 ± 1.7 0.682 ± 0.07 1.15 ± 0.02 23.73 ± 1.5 23.64 ± 2.5 1.07 ± 0.12 74.91 ± 2.1
Change
Placebo (%)
−4.77 ± 6.4 −4.70 ± 5.2 −2.38 ± 8.0 0.20 ± 15.4 2.26 ± 3.0 −12.32 ± 9.6 −0.72 ± 2.5 −9.90 ± 6.8 −9.29 ± 5.8 7.41 ± 17.4 −0.34 ± 2.4
Change
T20 (%)
−6.25 ± 5.5 2.42 ± 5.4 −11.76 ± 6.9 7.02 ± 15.9 2.73 ± 2.0 10.02 ± 11.3 4.10 ± 2.1 1.16 ± 6.3 6.12 ± 10.9 35.63 ± 14.3 0.86 ± 2.7
p value
change
0.937 0.200 0.798 0.695 0.656 0.060 0.194 0.722 0.192 0.349 0.473
p value
PREs
0.695 0.075 0.211 0.784 0.594 0.239 0.334 0.893 0.422 0.177 0.503

CHOL = Total cholesterol; HDL = High density lipoproteins; LDL = Low density lipoproteins; TAG = Triglycerides; GLU = Glucose; mtDNA = Mitochondrial DNA; Crt = Creatinine; AST = Aspartate aminotransferase; ALT = Alanine transferase; BIL = Bilirubin; PROTp = Total plasma proteins; PRE = Values before starting placebo/T20; POST = Values after starting placebo/T20.